PMID- 35480520
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220430
IS  - 1682-024X (Print)
IS  - 1681-715X (Electronic)
IS  - 1681-715X (Linking)
VI  - 38
IP  - 3Part-I
DP  - 2022 Mar-Apr
TI  - Intravenous thrombolysis with alteplase in the treatment of acute cerebral 
      infarction.
PG  - 498-504
LID - 10.12669/pjms.38.3.4521 [doi]
AB  - OBJECTIVES: To compare the efficacy and safety of intravenous thrombolysis with 
      alteplase and intravenous thrombolysis with urokinase for patients with acute 
      cerebral infarction. METHODS: This prospective study included 140 patients with 
      acute cerebral infarction who were admitted to our hospital between June 2018 and 
      June 2019. They were randomly divided into two groups. The control group (70 
      cases) was treated with urokinase intravenous thrombolysis, and the observation 
      group (70 cases) was given alteplase intravenous thrombolytic therapy. The 
      treatment efficacy and safety of the two groups were compared. RESULTS: The total 
      effective rate of the observation group was 95.7%, and that of the control group 
      was 78.6%, i.e., the total effective rate of the observation group was 
      significantly superior to the that of the control group (P < 0.05). After 
      treatment, the observation group had significantly lower National Institutes of 
      Health Stroke Scale (NIHSS) score and significantly higher mini-mental state 
      examination (MMSE) score than the control group; the difference was statistically 
      significant (P<0.05). After treatment, the levels of inflammatory factors of both 
      groups significantly decreased compared to before treatment, and the decrease in 
      the observation group was larger than that in the control group (P<0.05). The 
      levels of serum homocysteine (Hcy) and monocyte chemoattractant protein-1 (MCP-1) 
      in the observation group were significantly lower than those in the control group 
      after treatment, and the differences were statistically significant (P<0.05). The 
      incidence of hemorrhagic adverse reaction in the observation group was lower than 
      that in the control group (P<0.05). CONCLUSION: In the treatment of acute 
      cerebral infarction, ccompared with urokinase, alteplase can further relieve 
      cognitive impairment and promote the recovery of nerve function through 
      inhibiting levels of inflammatory factors and levels of serum Hcy and MCP-1.
CI  - Copyright: (c) Pakistan Journal of Medical Sciences.
FAU - Gao, Lilin
AU  - Gao L
AD  - Lilin Gao, Department of Neurology, Binzhou People's Hospital, Shandong 256610, 
      China.
FAU - Zhang, Shaojie
AU  - Zhang S
AD  - Shaojie Zhang, Department of Neurology, Binzhou People's Hospital, Shandong 
      256610, China.
FAU - Wo, Xuewen
AU  - Wo X
AD  - Xuewen Wo, Department of Neurology, Binzhou People's Hospital, Shandong 256610, 
      China.
FAU - Shen, Xiangpeng
AU  - Shen X
AD  - Xiangpeng Shen, Department of Neurology, Binzhou People's Hospital, Shandong 
      256610, China.
FAU - Tian, Qiangyuan
AU  - Tian Q
AD  - Qiangyuan Tian, Department of Neurology, Binzhou People's Hospital, Shandong 
      256610, China.
FAU - Wang, Guoqing
AU  - Wang G
AD  - Guoqing Wang, Department of Neurology, Binzhou People's Hospital, Shandong 
      256610, China.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - Pak J Med Sci
JT  - Pakistan journal of medical sciences
JID - 100913117
PMC - PMC9002439
OTO - NOTNLM
OT  - Acute cerebral infarction
OT  - Alteplase
OT  - Monocyte chemoattractant protein-1
OT  - Urokinase
EDAT- 2022/04/29 06:00
MHDA- 2022/04/29 06:01
PMCR- 2022/03/01
CRDT- 2022/04/28 06:30
PHST- 2021/04/06 00:00 [received]
PHST- 2021/10/09 00:00 [revised]
PHST- 2021/11/05 00:00 [revised]
PHST- 2021/11/18 00:00 [accepted]
PHST- 2022/04/28 06:30 [entrez]
PHST- 2022/04/29 06:00 [pubmed]
PHST- 2022/04/29 06:01 [medline]
PHST- 2022/03/01 00:00 [pmc-release]
AID - PJMS-38-498 [pii]
AID - 10.12669/pjms.38.3.4521 [doi]
PST - ppublish
SO  - Pak J Med Sci. 2022 Mar-Apr;38(3Part-I):498-504. doi: 10.12669/pjms.38.3.4521.